Escrito por estudiantes que aprobaron Inmediatamente disponible después del pago Leer en línea o como PDF ¿Documento equivocado? Cámbialo gratis 4,6 TrustPilot
logo-home
Document preview thumbnail
Vista previa 4 fuera de 39 páginas
Examen

NURS 6521 Final Exam 2025/2026 V3 Winter Quarter | Walden University | Advanced Pharmacology – Complete Exam with Accurate Questions & Answers

Document preview thumbnail
Vista previa 4 fuera de 39 páginas

This document provides the complete set of accurate questions and answers for the NURS 6521 Advanced Pharmacology Final Exam at Walden University, updated for the Winter Quarter 2025/2026. It covers essential pharmacology concepts, including pharmacokinetics, pharmacodynamics, prescriptive authority, major drug classes, adverse effects, drug interactions, evidence-based prescribing, and patient safety. Expert-verified and clinically aligned, this resource is designed to support exam success and advanced nursing practice.

Vista previa del contenido

NURS 6521 FINAL EXAM 2025/2026 V3 WINTER QUARTER |
WALDEN UNIVERSITY | ADVANCED PHARMACOLOGY –
COMPLETE EXAM WITH ACCURATE QUESTIONS &
ANSWERS
NURS 6521 Final Exam-Style Practice Paper
Advanced Pharmacology
Course: NURS 6521 – Advanced Pharmacology
Institution: Walden University
Academic Year: 2025–2026
Term: Winter Quarter
Version: V3-Style Practice Examination
Content: Comprehensive practice exam with multiple-choice and short-
answer questions, answers, and rationales
Author/Creator: Original AI-generated study material
Important note: This is an original practice examination designed for
study and review.


Table of Contents
1. Cardiovascular Pharmacology — Questions 1–15
2. Endocrine Pharmacology — Questions 16–28
3. Respiratory Pharmacology — Questions 29–38
4. Gastrointestinal Pharmacology — Questions 39–46
5. Neurologic and Psychiatric Pharmacology — Questions 47–62
6. Infectious Disease and Antimicrobial Pharmacology — Questions 63–75
7. Musculoskeletal, Rheumatologic, and Pain Pharmacology — Questions 76–
83

, 8. Women's Health and Genitourinary Pharmacology — Questions 84–90
9. Hematologic and Oncologic Pharmacology — Questions 91–95
10. Dermatologic, Immunologic, and Miscellaneous Pharmacology —
Questions 96–100


Section I — Cardiovascular Pharmacology

Question 1 — Multiple Choice

A patient with hypertension is prescribed lisinopril. Which laboratory value is most important to
monitor after initiation of therapy?

A. Serum amylase
B. Serum potassium and creatinine
C. Hemoglobin A1c
D. Serum calcium

Correct answer: B. Serum potassium and creatinine

Rationale:
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors can decrease
aldosterone-mediated potassium excretion, potentially causing hyperkalemia, and may alter renal
function. Serum creatinine and potassium should therefore be assessed after initiation and dose
changes. A mild increase in creatinine may occur, but a substantial increase requires evaluation
for renal dysfunction or renal artery stenosis.



Question 2 — Multiple Choice

Which adverse effect is most characteristic of ACE inhibitors?

A. Persistent dry cough
B. Severe constipation
C. Hypoglycemia
D. Ototoxicity

Correct answer: A. Persistent dry cough

Rationale:
ACE inhibition decreases degradation of bradykinin, which can accumulate in the respiratory
tract and produce a persistent, nonproductive cough. Angioedema is another potentially serious

,ACE-inhibitor adverse effect. If clinically significant cough develops, an angiotensin II receptor
blocker (ARB) may be considered.


Question 3 — Short Answer

A patient taking warfarin has an INR of 5.8 without active bleeding. What is the general
pharmacologic concern?

Correct answer:
The patient has excessive anticoagulation and an increased risk of bleeding; warfarin therapy
should be held or adjusted according to the clinical situation and current anticoagulation-
management guidance.

Rationale:
Warfarin has a narrow therapeutic index. An elevated INR indicates increased anticoagulant
effect and bleeding risk. Management depends on the INR, presence or absence of bleeding,
underlying indication, and thrombotic risk. Vitamin K may be used in selected circumstances,
but treatment should not be based on the INR alone.



Question 4 — Multiple Choice

Which medication is a direct oral factor Xa inhibitor?

A. Dabigatran
B. Apixaban
C. Warfarin
D. Clopidogrel

Correct answer: B. Apixaban
Rationale:
Apixaban directly inhibits factor Xa and reduces thrombin generation. Rivaroxaban and
edoxaban are also direct factor Xa inhibitors. Dabigatran is a direct thrombin inhibitor, while
warfarin inhibits vitamin K-dependent clotting-factor synthesis.



Question 5 — Multiple Choice

A patient taking spironolactone should be monitored most closely for:

A. Hypokalemia
B. Hyperkalemia

, C. Hypocalcemia
D. Hypernatremia

Correct answer: B. Hyperkalemia
Rationale:
Spironolactone is a potassium-sparing diuretic and aldosterone antagonist. Reduced renal
potassium excretion can result in hyperkalemia, particularly in patients with chronic kidney
disease or those taking ACE inhibitors, ARBs, or potassium supplements.



Question 6 — Multiple Choice

Which finding in a patient taking digoxin is most concerning for toxicity?

A. Increased appetite
B. Yellow-green visual disturbances and nausea
C. Mild thirst
D. Increased urinary frequency

Correct answer: B. Yellow-green visual disturbances and nausea

Rationale:
Digoxin toxicity can produce gastrointestinal symptoms, neurologic symptoms, cardiac
dysrhythmias, and visual disturbances such as blurred or yellow-green vision. Risk increases
with renal impairment and electrolyte abnormalities, especially hypokalemia.



Question 7 — Short Answer

Why can hypokalemia increase the risk of digoxin toxicity?
Correct answer:
Low potassium increases digoxin binding to the sodium-potassium ATPase receptor, thereby
increasing its pharmacologic and toxic effects.

Rationale:
Potassium and digoxin interact at the sodium-potassium ATPase. When potassium is low, digoxin
has greater receptor binding, increasing the likelihood of toxicity. This is one reason potassium
status should be monitored carefully in patients receiving digoxin and diuretics.



Question 8 — Multiple Choice

Which medication is most appropriate for rapid relief of an acute episode of stable angina?

Información del documento

Subido en
14 de agosto de 2026
Número de páginas
39
Escrito en
2026/2027
Tipo
Examen
Contiene
Preguntas y respuestas
$13.99

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Seller avatar
Los indicadores de reputación están sujetos a la cantidad de artículos vendidos por una tarifa y las reseñas que ha recibido por esos documentos. Hay tres niveles: Bronce, Plata y Oro. Cuanto mayor reputación, más podrás confiar en la calidad del trabajo del vendedor.
Edunursepro
4.0
(51)
Vendido
189
Seguidores
10
Artículos
10616
Última venta
16 horas hace



Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes